GLP-1 Antibody (11E2): sc-80603
- GLP-1 Antibody (11E2) is a mouse monoclonal IgG2a provided at 50 µg/0.5 ml
- raised against a GLP-1
- recommended for detection of all forms of GLP-1, including the precursor of mouse, rat, human and bovine origin by WB
- At present, we have not yet completed the identification of the preferred secondary detection reagent(s) for GLP-1 Antibody (11E2). This work is in progress.
GLP-1 Antibody (11E2) is a mouse monoclonal IgG2a antibody that detects glucagon-like peptide-1 (GLP-1) in mouse, rat, human, and bovine samples through western blotting (WB). GLP-1 plays a crucial role in glucose metabolism and appetite regulation, functioning as an incretin hormone that enhances insulin secretion in response to meals while simultaneously inhibiting glucagon release, thereby lowering blood sugar levels. GLP-1 is primarily produced in intestinal L-cells and secreted into the bloodstream, where GLP-1 acts on various tissues, including the pancreas and brain, to exert physiological effects. The localization of GLP-1 in the gut allows for rapid responses to nutrient intake, making GLP-1 a key player in maintaining glucose homeostasis and influencing satiety. Additionally, GLP-1 has been shown to promote pancreatic beta cell proliferation, which is vital for insulin production and overall metabolic health. Anti-GLP-1 antibody (11E2) serves as an essential tool for researchers studying glucose regulation mechanisms and potential therapeutic applications in conditions such as diabetes and obesity.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
GLP-1 Antibody (11E2) References:
- Novel GLP-1 receptor agonists for diabetes. | Garber, AJ. 2012. Expert Opin Investig Drugs. 21: 45-57. PMID: 22111970
- Anorexigenic effects of GLP-1 and its analogues. | Gallwitz, B. 2012. Handb Exp Pharmacol. 185-207. PMID: 22249815
- GLP-1 agonists for type 2 diabetes: pharmacokinetic and toxicological considerations. | Jespersen, MJ., et al. 2013. Expert Opin Drug Metab Toxicol. 9: 17-29. PMID: 23094590
- The GLP-1 agonist, liraglutide, as a pharmacotherapy for obesity. | Crane, J. and McGowan, B. 2016. Ther Adv Chronic Dis. 7: 92-107. PMID: 26977279
- GLP-1 Receptor Expression Within the Human Heart. | Baggio, LL., et al. 2018. Endocrinology. 159: 1570-1584. PMID: 29444223
- Activation of the GLP-1 receptor by a non-peptidic agonist. | Zhao, P., et al. 2020. Nature. 577: 432-436. PMID: 31915381
- The therapeutic potential of GLP-1 analogues for stress-related eating and role of GLP-1 in stress, emotion and mood: a review. | Guerrero-Hreins, E., et al. 2021. Prog Neuropsychopharmacol Biol Psychiatry. 110: 110303. PMID: 33741445
- GLP-1 Induces the Expression of FNDC5 Derivatives That Execute Lipolytic Actions. | Li, H., et al. 2021. Front Cell Dev Biol. 9: 777026. PMID: 34869379
- Design of Xenopus GLP-1-Based Long-Acting Dual GLP-1/Y2 Receptor Agonists. | Yang, Q., et al. 2022. J Med Chem. 65: 14201-14220. PMID: 36214844
- Topography of the GLP-1/GLP-1 receptor system in the spinal cord of male mice. | Ruska, Y., et al. 2024. Sci Rep. 14: 14403. PMID: 38909126
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
GLP-1 Antibody (11E2) | sc-80603 | 50 µg/0.5 ml | $322.00 |